Cargando…
Intravesical drug delivery approaches for improved therapy of urinary bladder diseases
Diseases of the urinary bladder have high incidence rates and burden healthcare costs. Their pharmacological treatment involves systemic and local drug administration. The latter is generally accomplished through instillation of liquid formulations and requires repeated or long-term catheterization...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569723/ https://www.ncbi.nlm.nih.gov/pubmed/34765967 http://dx.doi.org/10.1016/j.ijpx.2021.100100 |
_version_ | 1784594697497346048 |
---|---|
author | Palugan, Luca Cerea, Matteo Cirilli, Micol Moutaharrik, Saliha Maroni, Alessandra Zema, Lucia Melocchi, Alice Uboldi, Marco Filippin, Ilaria Foppoli, Anastasia Gazzaniga, Andrea |
author_facet | Palugan, Luca Cerea, Matteo Cirilli, Micol Moutaharrik, Saliha Maroni, Alessandra Zema, Lucia Melocchi, Alice Uboldi, Marco Filippin, Ilaria Foppoli, Anastasia Gazzaniga, Andrea |
author_sort | Palugan, Luca |
collection | PubMed |
description | Diseases of the urinary bladder have high incidence rates and burden healthcare costs. Their pharmacological treatment involves systemic and local drug administration. The latter is generally accomplished through instillation of liquid formulations and requires repeated or long-term catheterization that is associated with discomfort, inflammation and bacterial infections. Consequently, compliance issues and dropouts are frequently reported. Moreover, instilled drugs are progressively diluted as the urine volume increases and rapidly excreted. When penetration of drugs into the bladder wall is needed, the poor permeability of the urothelium has also to be accounted for. Therefore, much research effort is spent to overcome these hurdles, thereby improving the efficacy of available therapies. Particularly, indwelling delivery systems suited for i) insertion into the bladder through the urethra, ii) intra-organ retention and prolonged release for the desired time lapse, iii) final elimination, either spontaneous or by manual removal, have been proposed to reduce the number of catheterization procedures and reach higher drug levels at the target site. Vesical retention of such devices is allowed by the relevant expansion that can either be triggered from the outside or achieved exploiting elastic and purposely 4D printed shape memory materials. In this article, the main rationales and strategies for improved intravesical delivery are reviewed. |
format | Online Article Text |
id | pubmed-8569723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-85697232021-11-10 Intravesical drug delivery approaches for improved therapy of urinary bladder diseases Palugan, Luca Cerea, Matteo Cirilli, Micol Moutaharrik, Saliha Maroni, Alessandra Zema, Lucia Melocchi, Alice Uboldi, Marco Filippin, Ilaria Foppoli, Anastasia Gazzaniga, Andrea Int J Pharm X Review Paper Diseases of the urinary bladder have high incidence rates and burden healthcare costs. Their pharmacological treatment involves systemic and local drug administration. The latter is generally accomplished through instillation of liquid formulations and requires repeated or long-term catheterization that is associated with discomfort, inflammation and bacterial infections. Consequently, compliance issues and dropouts are frequently reported. Moreover, instilled drugs are progressively diluted as the urine volume increases and rapidly excreted. When penetration of drugs into the bladder wall is needed, the poor permeability of the urothelium has also to be accounted for. Therefore, much research effort is spent to overcome these hurdles, thereby improving the efficacy of available therapies. Particularly, indwelling delivery systems suited for i) insertion into the bladder through the urethra, ii) intra-organ retention and prolonged release for the desired time lapse, iii) final elimination, either spontaneous or by manual removal, have been proposed to reduce the number of catheterization procedures and reach higher drug levels at the target site. Vesical retention of such devices is allowed by the relevant expansion that can either be triggered from the outside or achieved exploiting elastic and purposely 4D printed shape memory materials. In this article, the main rationales and strategies for improved intravesical delivery are reviewed. Elsevier 2021-10-23 /pmc/articles/PMC8569723/ /pubmed/34765967 http://dx.doi.org/10.1016/j.ijpx.2021.100100 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Paper Palugan, Luca Cerea, Matteo Cirilli, Micol Moutaharrik, Saliha Maroni, Alessandra Zema, Lucia Melocchi, Alice Uboldi, Marco Filippin, Ilaria Foppoli, Anastasia Gazzaniga, Andrea Intravesical drug delivery approaches for improved therapy of urinary bladder diseases |
title | Intravesical drug delivery approaches for improved therapy of urinary bladder diseases |
title_full | Intravesical drug delivery approaches for improved therapy of urinary bladder diseases |
title_fullStr | Intravesical drug delivery approaches for improved therapy of urinary bladder diseases |
title_full_unstemmed | Intravesical drug delivery approaches for improved therapy of urinary bladder diseases |
title_short | Intravesical drug delivery approaches for improved therapy of urinary bladder diseases |
title_sort | intravesical drug delivery approaches for improved therapy of urinary bladder diseases |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569723/ https://www.ncbi.nlm.nih.gov/pubmed/34765967 http://dx.doi.org/10.1016/j.ijpx.2021.100100 |
work_keys_str_mv | AT paluganluca intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT cereamatteo intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT cirillimicol intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT moutaharriksaliha intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT maronialessandra intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT zemalucia intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT melocchialice intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT uboldimarco intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT filippinilaria intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT foppolianastasia intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases AT gazzanigaandrea intravesicaldrugdeliveryapproachesforimprovedtherapyofurinarybladderdiseases |